242 related articles for article (PubMed ID: 26740214)
1. Identification of six pathogenic RAD51C mutations via mutational screening of 1228 Danish individuals with increased risk of hereditary breast and/or ovarian cancer.
Jønson L; Ahlborn LB; Steffensen AY; Djursby M; Ejlertsen B; Timshel S; Nielsen FC; Gerdes AM; Hansen TV
Breast Cancer Res Treat; 2016 Jan; 155(2):215-22. PubMed ID: 26740214
[TBL] [Abstract][Full Text] [Related]
2. RAD51C mutation screening in high-risk patients from Serbian hereditary breast/ovarian cancer families.
Krivokuca A; Yanowski K; Rakobradovic J; Benitez J; Brankovic-Magic M
Cancer Biomark; 2015; 15(6):775-81. PubMed ID: 26406419
[TBL] [Abstract][Full Text] [Related]
3. Deleterious RAD51C germline mutations rarely predispose to breast and ovarian cancer in Pakistan.
Rashid MU; Muhammad N; Faisal S; Amin A; Hamann U
Breast Cancer Res Treat; 2014 Jun; 145(3):775-84. PubMed ID: 24800917
[TBL] [Abstract][Full Text] [Related]
4. RAD51C germline mutations found in Spanish site-specific breast cancer and breast-ovarian cancer families.
Blanco A; Gutiérrez-Enríquez S; Santamariña M; Montalban G; Bonache S; Balmaña J; Carracedo A; Diez O; Vega A
Breast Cancer Res Treat; 2014 Aug; 147(1):133-43. PubMed ID: 25086635
[TBL] [Abstract][Full Text] [Related]
5. Analysis of RAD51C germline mutations in high-risk breast and ovarian cancer families and ovarian cancer patients.
Thompson ER; Boyle SE; Johnson J; Ryland GL; Sawyer S; Choong DY; kConFab ; Chenevix-Trench G; Trainer AH; Lindeman GJ; Mitchell G; James PA; Campbell IG
Hum Mutat; 2012 Jan; 33(1):95-9. PubMed ID: 21990120
[TBL] [Abstract][Full Text] [Related]
6. Predominance of pathogenic missense variants in the RAD51C gene occurring in breast and ovarian cancer families.
Osorio A; Endt D; Fernández F; Eirich K; de la Hoya M; Schmutzler R; Caldés T; Meindl A; Schindler D; Benitez J
Hum Mol Genet; 2012 Jul; 21(13):2889-98. PubMed ID: 22451500
[TBL] [Abstract][Full Text] [Related]
7. Screening RAD51C nucleotide alterations in patients with a family history of breast and ovarian cancer.
Zheng Y; Zhang J; Hope K; Niu Q; Huo D; Olopade OI
Breast Cancer Res Treat; 2010 Dec; 124(3):857-61. PubMed ID: 20697805
[TBL] [Abstract][Full Text] [Related]
8. Further evidence for the contribution of the RAD51C gene in hereditary breast and ovarian cancer susceptibility.
Vuorela M; Pylkäs K; Hartikainen JM; Sundfeldt K; Lindblom A; von Wachenfeldt Wäppling A; Haanpää M; Puistola U; Rosengren A; Anttila M; Kosma VM; Mannermaa A; Winqvist R
Breast Cancer Res Treat; 2011 Dec; 130(3):1003-10. PubMed ID: 21750962
[TBL] [Abstract][Full Text] [Related]
9. Germline mutations in RAD51C in Jewish high cancer risk families.
Kushnir A; Laitman Y; Shimon SP; Berger R; Friedman E
Breast Cancer Res Treat; 2012 Dec; 136(3):869-74. PubMed ID: 23117857
[TBL] [Abstract][Full Text] [Related]
10. Genetic testing for RAD51C mutations: in the clinic and community.
Sopik V; Akbari MR; Narod SA
Clin Genet; 2015 Oct; 88(4):303-12. PubMed ID: 25470109
[TBL] [Abstract][Full Text] [Related]
11. RAD51C germline mutations in breast and ovarian cancer cases from high-risk families.
Clague J; Wilhoite G; Adamson A; Bailis A; Weitzel JN; Neuhausen SL
PLoS One; 2011; 6(9):e25632. PubMed ID: 21980511
[TBL] [Abstract][Full Text] [Related]
12. Screening of 1331 Danish breast and/or ovarian cancer families identified 40 novel BRCA1 and BRCA2 mutations.
Hansen TV; Jønson L; Steffensen AY; Andersen MK; Kjaergaard S; Gerdes AM; Ejlertsen B; Nielsen FC
Fam Cancer; 2011 Jun; 10(2):207-12. PubMed ID: 21318380
[TBL] [Abstract][Full Text] [Related]
13. Gene-panel testing of breast and ovarian cancer patients identifies a recurrent RAD51C duplication.
Pelttari LM; Shimelis H; Toiminen H; Kvist A; Törngren T; Borg Å; Blomqvist C; Bützow R; Couch F; Aittomäki K; Nevanlinna H
Clin Genet; 2018 Mar; 93(3):595-602. PubMed ID: 28802053
[TBL] [Abstract][Full Text] [Related]
14. Germline RAD51C mutations in ovarian cancer susceptibility.
Coulet F; Fajac A; Colas C; Eyries M; Dion-Minière A; Rouzier R; Uzan S; Lefranc JP; Carbonnel M; Cornelis F; Cortez A; Soubrier F
Clin Genet; 2013 Apr; 83(4):332-6. PubMed ID: 22725699
[TBL] [Abstract][Full Text] [Related]
15. Mutation screening of RAD51C in high-risk breast and ovarian cancer families.
Lu W; Wang X; Lin H; Lindor NM; Couch FJ
Fam Cancer; 2012 Sep; 11(3):381-5. PubMed ID: 22476429
[TBL] [Abstract][Full Text] [Related]
16. Mutation Analysis of the RAD51C and RAD51D Genes in High-Risk Ovarian Cancer Patients and Families from the Czech Republic.
Janatova M; Soukupova J; Stribrna J; Kleiblova P; Vocka M; Boudova P; Kleibl Z; Pohlreich P
PLoS One; 2015; 10(6):e0127711. PubMed ID: 26057125
[TBL] [Abstract][Full Text] [Related]
17. RAD51C is a susceptibility gene for ovarian cancer.
Pelttari LM; Heikkinen T; Thompson D; Kallioniemi A; Schleutker J; Holli K; Blomqvist C; Aittomäki K; Bützow R; Nevanlinna H
Hum Mol Genet; 2011 Aug; 20(16):3278-88. PubMed ID: 21616938
[TBL] [Abstract][Full Text] [Related]
18. Mutational analysis of RAD51C and RAD51D genes in hereditary breast and ovarian cancer families from Murcia (southeastern Spain).
Sánchez-Bermúdez AI; Sarabia-Meseguer MD; García-Aliaga Á; Marín-Vera M; Macías-Cerrolaza JA; Henaréjos PS; Guardiola-Castillo V; Peña FA; Alonso-Romero JL; Noguera-Velasco JA; Ruiz-Espejo F
Eur J Med Genet; 2018 Jun; 61(6):355-361. PubMed ID: 29409816
[TBL] [Abstract][Full Text] [Related]
19. BRIP1, PALB2, and RAD51C mutation analysis reveals their relative importance as genetic susceptibility factors for breast cancer.
Wong MW; Nordfors C; Mossman D; Pecenpetelovska G; Avery-Kiejda KA; Talseth-Palmer B; Bowden NA; Scott RJ
Breast Cancer Res Treat; 2011 Jun; 127(3):853-9. PubMed ID: 21409391
[TBL] [Abstract][Full Text] [Related]
20. The RAD51C exonic splice-site mutations c.404G>C and c.404G>T are associated with familial breast and ovarian cancer.
Neidhardt G; Becker A; Hauke J; Horváth J; Bogdanova Markov N; Heilmann-Heimbach S; Hellebrand H; Thiele H; Altmüller J; Nürnberg P; Meindl A; Rhiem K; Blümcke B; Wappenschmidt B; Schmutzler RK; Hahnen E
Eur J Cancer Prev; 2017 Mar; 26(2):165-169. PubMed ID: 27622768
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
